Oct 6, 2025 · Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability.

Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance …

Mar 17, 2025 · Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical …

At Harrow, our values aren’t just guiding words—they shape how we grow, innovate, and work together. Humility, ownership, preparedness, and entrepreneurship create the foundation for a culture where …

SAN DIEGO , May 5, 2016 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and …

Prior to joining Harrow, he was Founder and Chief Executive Officer of LVMA Consulting, advising emerging biotech companies and top 10 global pharmaceutical organizations on commercial …

Harrow INC SEC filing: Form 8-K iXBRL on 09/09/2025 (0001493152-25-012840).

www.harrow.com

The content provided by Harrow on this web site and all site-related services is intended to educate and inform you about Harrow, our product candidates and our technology.

harrow health inc-2 harrow health inc-1 harrow health inc Harrow Health INC 2,145,767 shares of common stock available for award under the Company’s 2017 Incentive Stock and Awards Plan (the …